Financings in Brief: Sonus Pharmaceuticals
This article was originally published in The Gray Sheet
Sonus Pharmaceuticals: Raises $19.4 mil. in recently completed initial public offering of 3.3 mil. shares of common stock at $7 each. The shares sold included the initial 2.85 mil. shares offered plus the entire underwriters' over-allotment option of 427,000 shares ("The Gray Sheet" Oct. 16, p. 6). The firm now has about 8.4 mil. shares outstanding. Underwriters were Hambrecht & Quist, Montgomery Securities, and UBS Securities...
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.